As Amgen's Aimovig Momentum Continues, Challenges To Current Blockbusters Loom Large

 
• By Mandy Jackson

Q1 Earnings Preview: While investors will look for updates on Aimovig and Evenity launches and a recently revealed legal battle with partner Novartis, Amgen's current blockbusters also are in the hotseat.

Machinery cogwheels, industry concept
Many challenges could affect Amgen's finely tuned machine

More from Earnings

More from Business